Loading...

REGENXBIO

Nasdaq:RGNX
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RGNX
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
RGNX Share Price and Events
7 Day Returns
3.4%
NasdaqGS:RGNX
5.9%
US Biotechs
2.2%
US Market
1 Year Returns
-25.3%
NasdaqGS:RGNX
-4.3%
US Biotechs
3.8%
US Market
RGNX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
REGENXBIO (RGNX) 3.4% 16.5% -7.5% -25.3% 564.8% -
US Biotechs 5.9% 4.6% 1.7% -4.3% 22.4% 12%
US Market 2.2% 4.2% 4.4% 3.8% 43% 40.9%
1 Year Return vs Industry and Market
  • RGNX underperformed the Biotechs industry which returned -4.3% over the past year.
  • RGNX underperformed the Market in United States of America which returned 3.8% over the past year.
Price Volatility
RGNX
Industry
5yr Volatility vs Market
Related Companies

Value

 Is REGENXBIO undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of REGENXBIO to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for REGENXBIO.

NasdaqGS:RGNX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:RGNX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.325 (1 + (1- 21%) (0.4%))
1.22
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.22 * 5.96%)
10%

Discounted Cash Flow Calculation for NasdaqGS:RGNX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for REGENXBIO is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:RGNX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10%)
2019 -86.45 Analyst x2 -78.59
2020 61.45 Analyst x2 50.78
2021 64.00 Analyst x2 48.08
2022 189.75 Analyst x2 129.58
2023 102.10 Analyst x2 63.39
2024 59.98 Est @ -41.25% 33.85
2025 43.15 Est @ -28.06% 22.14
2026 35.03 Est @ -18.82% 16.34
2027 30.70 Est @ -12.36% 13.02
2028 28.30 Est @ -7.83% 10.91
Present value of next 10 years cash flows $309.49
NasdaqGS:RGNX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $28.30 × (1 + 2.73%) ÷ (10% – 2.73%)
$399.63
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $399.63 ÷ (1 + 10%)10
$154.02
NasdaqGS:RGNX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $309.49 + $154.02
$463.51
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $463.51 / 36.64
$12.65
NasdaqGS:RGNX Discount to Share Price
Calculation Result
Value per share (USD) From above. $12.65
Current discount Discount to share price of $53.18
= -1 x ($53.18 - $12.65) / $12.65
-320.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of REGENXBIO is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for REGENXBIO's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are REGENXBIO's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:RGNX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.06
NasdaqGS:RGNX Share Price ** NasdaqGS (2019-06-21) in USD $53.18
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of REGENXBIO.

NasdaqGS:RGNX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RGNX Share Price ÷ EPS (both in USD)

= 53.18 ÷ -1.06

-50.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REGENXBIO is loss making, we can't compare its value to the US Biotechs industry average.
  • REGENXBIO is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does REGENXBIO's expected growth come at a high price?
Raw Data
NasdaqGS:RGNX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -50.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
69.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.04x
United States of America Market PEG Ratio Median Figure of 2,134 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for REGENXBIO, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on REGENXBIO's assets?
Raw Data
NasdaqGS:RGNX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $13.30
NasdaqGS:RGNX Share Price * NasdaqGS (2019-06-21) in USD $53.18
United States of America Biotechs Industry PB Ratio Median Figure of 431 Publicly-Listed Biotechs Companies 3.01x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.81x
NasdaqGS:RGNX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RGNX Share Price ÷ Book Value per Share (both in USD)

= 53.18 ÷ 13.30

4x

* Primary Listing of REGENXBIO.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REGENXBIO is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess REGENXBIO's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. REGENXBIO has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is REGENXBIO expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
69.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is REGENXBIO expected to grow at an attractive rate?
  • REGENXBIO's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • REGENXBIO's earnings growth is expected to exceed the United States of America market average.
  • REGENXBIO's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:RGNX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:RGNX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 69.8%
NasdaqGS:RGNX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 40.9%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:RGNX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:RGNX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 456 206 101 2
2022-12-31 406 167 193 2
2021-12-31 198 97 13 4
2020-12-31 172 -28 7 4
2019-12-31 53 -67 -100 4
NasdaqGS:RGNX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 87 17 -37
2018-12-31 219 105 100
2018-09-30 180 95 80
2018-06-30 176 97 78
2018-03-31 142 18 53
2017-12-31 10 -58 -73
2017-09-30 10 -65 -77
2017-06-30 9 -59 -74
2017-03-31 5 -58 -74
2016-12-31 5 -49 -63
2016-09-30 7 -33 -49
2016-06-30 8 -29 -38

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • REGENXBIO's earnings are expected to grow significantly at over 20% yearly.
  • REGENXBIO's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:RGNX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from REGENXBIO Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:RGNX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.76 6.35 -0.84 2.00
2022-12-31 5.23 6.89 3.56 2.00
2021-12-31 0.45 3.33 -1.93 4.00
2020-12-31 0.20 4.02 -1.91 3.00
2019-12-31 -2.62 -2.36 -2.99 3.00
NasdaqGS:RGNX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.06
2018-12-31 2.99
2018-09-30 2.47
2018-06-30 2.48
2018-03-31 1.71
2017-12-31 -2.45
2017-09-30 -2.68
2017-06-30 -2.69
2017-03-31 -2.80
2016-12-31 -2.38
2016-09-30 -1.84
2016-06-30 -1.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if REGENXBIO will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess REGENXBIO's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
REGENXBIO has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has REGENXBIO performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare REGENXBIO's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • REGENXBIO does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare REGENXBIO's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare REGENXBIO's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
REGENXBIO's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from REGENXBIO Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:RGNX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 87.00 -36.53 40.03
2018-12-31 218.51 99.94 36.85
2018-09-30 179.77 79.63 30.51
2018-06-30 175.80 78.13 30.95
2018-03-31 142.33 53.06 28.99
2017-12-31 10.39 -73.17 27.23
2017-09-30 10.05 -76.78 28.16
2017-06-30 8.84 -74.23 24.92
2017-03-31 4.65 -74.19 24.73
2016-12-31 4.59 -62.97 23.59
2016-09-30 7.34 -48.54 22.09
2016-06-30 8.35 -37.72 18.45
2016-03-31 7.34 -32.07 15.68
2015-12-31 7.59 -23.80 11.91
2015-09-30 4.29 -21.18 8.79
2015-06-30 3.64 -15.76 7.30
2015-03-31 3.83 -7.53 4.93
2014-12-31 6.12 -4.82 3.85
2013-12-31 6.09 -5.81 5.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if REGENXBIO has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if REGENXBIO has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if REGENXBIO improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess REGENXBIO's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
REGENXBIO has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is REGENXBIO's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up REGENXBIO's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • REGENXBIO is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • REGENXBIO's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of REGENXBIO's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.4214296729096E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from REGENXBIO Company Filings, last reported 2 months ago.

NasdaqGS:RGNX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 487.05 0.00 285.23
2018-12-31 508.85 0.00 319.76
2018-09-30 494.06 0.00 372.59
2018-06-30 317.22 0.00 286.49
2018-03-31 299.34 0.00 229.87
2017-12-31 183.03 0.00 160.78
2017-09-30 194.65 0.00 166.66
2017-06-30 211.70 0.00 162.08
2017-03-31 212.90 0.00 145.81
2016-12-31 161.74 0.00 89.55
2016-09-30 180.23 0.00 91.77
2016-06-30 196.18 0.00 94.21
2016-03-31 208.60 0.00 101.06
2015-12-31 216.81 0.00 114.14
2015-09-30 221.81 0.00 213.35
2015-06-30 82.63 0.00 85.22
2015-03-31 20.20 0.00 25.37
2014-12-31 -5.70 3.83 1.12
2013-12-31 -2.14 0.66 1.12
  • REGENXBIO's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • REGENXBIO had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making REGENXBIO has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making REGENXBIO has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -76.2% per year.
X
Financial health checks
We assess REGENXBIO's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. REGENXBIO has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is REGENXBIO's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from REGENXBIO dividends.
If you bought $2,000 of REGENXBIO shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate REGENXBIO's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate REGENXBIO's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:RGNX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:RGNX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as REGENXBIO has not reported any payouts.
  • Unable to verify if REGENXBIO's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of REGENXBIO's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as REGENXBIO has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess REGENXBIO's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can REGENXBIO afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. REGENXBIO has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of REGENXBIO's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ken Mills
COMPENSATION $4,938,199
AGE 43
TENURE AS CEO 10.3 years
CEO Bio

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills served as the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, where he worked as part of the founding management establish its operations and ongoing business strategy. As part of his responsibilities, Mr. Mills supervised all company affairs, including direct management of corporate and business development, strategic planning, as well as finance and accounting activities. Mr. Mills has been a Director of REGENXBIO Inc. since March 2009. He served as a Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

CEO Compensation
  • Ken's compensation has increased whilst company is loss making.
  • Ken's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the REGENXBIO management team in years:

2.5
Average Tenure
48.5
Average Age
  • The tenure for the REGENXBIO management team is about average.
Management Team

Ken Mills

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
43
TENURE
10.3 yrs

Vit Vasista

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
50
TENURE
9.8 yrs

Curran Simpson

TITLE
Senior VP of Product Development & Chief Technology Officer
COMPENSATION
$2M
AGE
56
TENURE
3.8 yrs

Olivier Danos

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
60
TENURE
2.3 yrs

Stephen Yoo

TITLE
Consultant
COMPENSATION
$2M
AGE
40
TENURE
0.5 yrs

Patrick Christmas

TITLE
Senior VP & General Counsel
AGE
47
TENURE
2.8 yrs

Andrew Yost

TITLE
Vice President of Corporate Development
TENURE
2.3 yrs

Shiva Fritsch

TITLE
Senior Vice President of Human Resources
TENURE
1.7 yrs

Laura Coruzzi

TITLE
Senior Vice President of Intellectual Property
TENURE
3.1 yrs

Ram Palanki

TITLE
Senior VP of Commercial Strategy & Operations
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the REGENXBIO board of directors in years:

4.1
Average Tenure
64.5
Average Age
  • The tenure for the REGENXBIO board of directors is about average.
Board of Directors

Don Hayden

TITLE
Chairman of the Board
COMPENSATION
$471K
AGE
62
TENURE
6.3 yrs

Ken Mills

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
43
TENURE
10.3 yrs

Luke Beshar

TITLE
Independent Director
COMPENSATION
$451K
AGE
59
TENURE
4.2 yrs

Jerry Karabelas

TITLE
Independent Director
COMPENSATION
$439K
AGE
66
TENURE
4.1 yrs

Allan Fox

TITLE
Director
COMPENSATION
$431K
AGE
70
TENURE
10.3 yrs

Judith Swain

TITLE
Member of Scientific Advisor
AGE
69

Inder Verma

TITLE
Member of Scientific Advisor
AGE
70

Dave Stump

TITLE
Independent Director
COMPENSATION
$442K
AGE
68
TENURE
3.7 yrs

Dan Abdun-Nabi

TITLE
Independent Director
COMPENSATION
$438K
AGE
63
TENURE
2.8 yrs

Daniel Tassé

TITLE
Independent Director
COMPENSATION
$436K
AGE
58
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess REGENXBIO's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. REGENXBIO has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Calculating The Fair Value Of REGENXBIO Inc. (NASDAQ:RGNX)

Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. … We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. … Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars: 10-year free cash flow (FCF) forecast 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $-86.45 $61.45 $64.00 $189.75 $183.00 $179.86 $179.17 $180.15 $182.32 $185.35 Growth Rate Estimate Source Analyst x2 Analyst x2 Analyst x2 Analyst x2 Analyst x1 Est @ -1.72% Est @ -0.38% Est @ 0.55% Est @ 1.2% Est @ 1.66% Present Value ($, Millions) Discounted @ 10% $-78.59 $50.79 $48.09 $129.62 $113.65 $101.55 $91.97 $84.07 $77.35 $71.49 Present Value of 10-year Cash Flow (PVCF)= $689.98m "Est" = FCF growth rate estimated by Simply Wall St The second stage is also known as Terminal Value, this is the business's cash flow after the first stage.

Simply Wall St -

REGENXBIO (NASDAQ:RGNX) Shareholders Have Enjoyed A Whopping 378% Share Price Gain

(NASDAQ:RGNX) share price, which skyrocketed 378% over three years. … It's also good to see the share price up 25% over the last quarter. … Given the importance of this milestone, it's not overly surprising that the share price has increased strongly.

Simply Wall St -

Is REGENXBIO Inc. (NASDAQ:RGNX) As Strong As Its Balance Sheet Indicates?

(NASDAQ:RGNX) with a market capitalization of US$2.1b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. … While they are less talked about as an investment category, mid-cap risk-adjusted returns have generally been better than more commonly focused stocks that fall into the small- or large-cap categories. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis.

Simply Wall St -

Did REGENXBIO Inc. (NASDAQ:RGNX) Use Debt To Deliver Its ROE Of 16%?

Our data shows REGENXBIO has a return on equity of 16% for the last year. … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.16 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is REGENXBIO Inc. (NASDAQ:RGNX) Worth US$43.81 Based On Intrinsic Value?

by taking the expected future cash flows and discounting them to today's value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Is REGENXBIO Inc. (NASDAQ:RGNX) A Financially Sound Company?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does RGNX's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt

Simply Wall St -

REGENXBIO Inc (NASDAQ:RGNX): Financial Strength Analysis

Surprisingly though, when accounted for risk, mid-caps have delivered better returns compared to the two other categories of stocks. … This article will examine RGNX’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … Don’t forget that this is a general and concentrated examination of REGENXBIO's financial health, so you should conduct further analysis.

Simply Wall St -

What Does REGENXBIO Inc's (NASDAQ:RGNX) PE Ratio Tell You?

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market. … and want to learn about the link between company’s fundamentals and stock market performance. … While RGNX might seem like an attractive stock to buy, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions.

Simply Wall St -

Is REGENXBIO Inc's (NASDAQ:RGNX) CEO Pay Fair?

Recognizing whether CEO incentives are aligned with shareholders is a crucial part of investing. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor. … CEOs leading companies of similar size and profitability

Simply Wall St -

Why REGENXBIO Inc's (NASDAQ:RGNX) ROE Of 17.73% Does Not Tell The Whole Story

This analysis is intended to introduce important early concepts to people who are starting to invest. … and want to start learning about core concepts of fundamental analysis on practical examples from today's market. … See our latest analysis for REGENXBIO

Simply Wall St -

Company Info

Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company’s lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Details
Name: REGENXBIO Inc.
RGNX
Exchange: NasdaqGS
Founded: 2008
$1,948,712,721
36,636,825
Website: http://www.regenxbio.com
Address: REGENXBIO Inc.
9600 Blackwell Road,
Suite 210,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RGNX Common Shares Nasdaq Global Select US USD 17. Sep 2015
DB RB0 Common Shares Deutsche Boerse AG DE EUR 17. Sep 2015
Number of employees
Current staff
Staff numbers
192
REGENXBIO employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/24 00:43
End of day share price update: 2019/06/21 00:00
Last estimates confirmation: 2019/06/18
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.